D
Integra LifeSciences Holdings Corporation
IART
$23.95
$1.345.93%
D
Sell
5/9/2024Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D from D+ on 5/9/2024 due to a large decline in the efficiency index, growth index and total return index. Earnings per share declined from $0.2518 to -$0.0422, net income declined 116.54% from $19.83M to -$3.28M, and operating cash flow declined 73.18% from $58.75M to $15.76M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D from D+ on 5/9/2024 due to a large decline in the efficiency index, growth index and total return index. Earnings per share declined from $0.2518 to -$0.0422, net income declined 116.54% from $19.83M to -$3.28M, and operating cash flow declined 73.18% from $58.75M to $15.76M.
D
Sell
3/4/2024Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 3/4/2024 due to a large decline in the growth index, valuation index and efficiency index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 3/4/2024 due to a large decline in the growth index, valuation index and efficiency index.
C
Hold
1/8/2024Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 1/8/2024 due to an increase in the total return index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 1/8/2024 due to an increase in the total return index and volatility index.
D
Sell
12/19/2023Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 12/19/2023 due to a decline in the valuation index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 12/19/2023 due to a decline in the valuation index and volatility index.
C
Hold
12/4/2023Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 12/4/2023 due to an increase in the volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 12/4/2023 due to an increase in the volatility index.
D
Sell
11/16/2023Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 11/16/2023 due to a decline in the valuation index, total return index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 11/16/2023 due to a decline in the valuation index, total return index and volatility index.
C
Hold
11/1/2023Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 11/1/2023 due to an increase in the total return index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 11/1/2023 due to an increase in the total return index.
D
Sell
10/2/2023Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 10/2/2023 due to a decline in the volatility index, total return index and solvency index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 10/2/2023 due to a decline in the volatility index, total return index and solvency index.
C
Hold
9/15/2023Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 9/15/2023 due to an increase in the valuation index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 9/15/2023 due to an increase in the valuation index and volatility index.
D
Sell
8/28/2023Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 8/28/2023 due to a noticeable decline in the valuation index, total return index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 8/28/2023 due to a noticeable decline in the valuation index, total return index and volatility index.
C
Hold
6/20/2023Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 6/20/2023 due to a large decline in the growth index, volatility index and solvency index. Operating cash flow declined 69.35% from $85.33M to $26.16M, earnings per share declined from $0.6303 to $0.29, and EBIT declined 25.08% from $81.28M to $60.9M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 6/20/2023 due to a large decline in the growth index, volatility index and solvency index. Operating cash flow declined 69.35% from $85.33M to $26.16M, earnings per share declined from $0.6303 to $0.29, and EBIT declined 25.08% from $81.28M to $60.9M.
C
Hold
1/11/2023Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 1/11/2023 due to an increase in the volatility index and total return index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 1/11/2023 due to an increase in the volatility index and total return index.
C
Hold
12/12/2022Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 12/12/2022 due to an increase in the volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C- from D+ on 12/12/2022 due to an increase in the volatility index.
D
Sell
11/23/2022Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 11/23/2022 due to a noticeable decline in the growth index, total return index and valuation index. Total revenue declined 3.17% from $397.82M to $385.19M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D+ from C- on 11/23/2022 due to a noticeable decline in the growth index, total return index and valuation index. Total revenue declined 3.17% from $397.82M to $385.19M.
C
Hold
9/7/2022Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 9/7/2022 due to a large decline in the volatility index and total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 9/7/2022 due to a large decline in the volatility index and total return index.
C
Hold
5/3/2022Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 5/3/2022 due to a major decline in the growth index, valuation index and volatility index. Operating cash flow declined 35.99% from $69.28M to $44.34M, earnings per share declined from $0.5291 to $0.39, and EBIT declined 21.45% from $80.42M to $63.16M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 5/3/2022 due to a major decline in the growth index, valuation index and volatility index. Operating cash flow declined 35.99% from $69.28M to $44.34M, earnings per share declined from $0.5291 to $0.39, and EBIT declined 21.45% from $80.42M to $63.16M.
C
Hold
4/19/2022Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 4/19/2022 due to a large decline in the total return index, efficiency index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 4/19/2022 due to a large decline in the total return index, efficiency index and volatility index.
B
Buy
11/3/2021Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B- from C+ on 11/3/2021 due to an increase in the total return index, solvency index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B- from C+ on 11/3/2021 due to an increase in the total return index, solvency index and volatility index.
C
Hold
10/11/2021Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 10/11/2021 due to a decline in the total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 10/11/2021 due to a decline in the total return index.
B
Buy
9/3/2021Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B- from C+ on 9/3/2021 due to an increase in the total return index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B- from C+ on 9/3/2021 due to an increase in the total return index and volatility index.
C
Hold
7/30/2021Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 7/30/2021 due to a major increase in the growth index, efficiency index and volatility index. Operating cash flow increased 32.15% from $69.08M to $91.29M, EBIT increased 21.67% from $57.9M to $70.45M, and total revenue increased 8.31% from $360.07M to $389.99M.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 7/30/2021 due to a major increase in the growth index, efficiency index and volatility index. Operating cash flow increased 32.15% from $69.08M to $91.29M, EBIT increased 21.67% from $57.9M to $70.45M, and total revenue increased 8.31% from $360.07M to $389.99M.
C
Hold
7/6/2021Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 7/6/2021 due to a decline in the total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 7/6/2021 due to a decline in the total return index.
C
Hold
6/21/2021Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 6/21/2021 due to an increase in the volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 6/21/2021 due to an increase in the volatility index.
C
Hold
6/3/2021Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 6/3/2021 due to a major decline in the growth index. Earnings per share declined from $1.092 to $0.53, EBIT declined 28.12% from $80.56M to $57.9M, and operating cash flow declined 13.93% from $80.26M to $69.08M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 6/3/2021 due to a major decline in the growth index. Earnings per share declined from $1.092 to $0.53, EBIT declined 28.12% from $80.56M to $57.9M, and operating cash flow declined 13.93% from $80.26M to $69.08M.
C
Hold
2/25/2021Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 2/25/2021 due to a substantial increase in the total return index, valuation index and efficiency index. Net income increased 186.8% from $32.34M to $92.74M, and total capital increased 4.33% from $3.13B to $3.26B.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 2/25/2021 due to a substantial increase in the total return index, valuation index and efficiency index. Net income increased 186.8% from $32.34M to $92.74M, and total capital increased 4.33% from $3.13B to $3.26B.
C
Hold
11/9/2020Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from D on 11/9/2020 due to a significant increase in the growth index, efficiency index and valuation index. Net income increased 8,863.41% from -$369 to $32.34M, earnings per share increased from -$0.0044 to $0.38, and EBIT increased 220.81% from $22.27M to $71.44M.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from D on 11/9/2020 due to a significant increase in the growth index, efficiency index and valuation index. Net income increased 8,863.41% from -$369 to $32.34M, earnings per share increased from -$0.0044 to $0.38, and EBIT increased 220.81% from $22.27M to $71.44M.
D
Sell
8/13/2020Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D from D+ on 8/13/2020 due to a decline in the efficiency index, growth index and valuation index. Earnings per share declined from $0.1078 to -$0.0044, net income declined 104.02% from $9.18M to -$369, and EBIT declined 51.26% from $45.69M to $22.27M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D from D+ on 8/13/2020 due to a decline in the efficiency index, growth index and valuation index. Earnings per share declined from $0.1078 to -$0.0044, net income declined 104.02% from $9.18M to -$369, and EBIT declined 51.26% from $45.69M to $22.27M.
D
Sell
8/10/2020Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to D+ from D on 8/10/2020 due to an increase in the volatility index and valuation index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to D+ from D on 8/10/2020 due to an increase in the volatility index and valuation index.
D
Sell
5/11/2020Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to D from C- on 5/11/2020 due to a major decline in the growth index, efficiency index and total return index. Operating cash flow declined 76.66% from $89.18M to $20.81M, net income declined 40.07% from $15.32M to $9.18M, and earnings per share declined from $0.1765 to $0.1078.
Integra LifeSciences Holdings Corporation (IART) was downgraded to D from C- on 5/11/2020 due to a major decline in the growth index, efficiency index and total return index. Operating cash flow declined 76.66% from $89.18M to $20.81M, net income declined 40.07% from $15.32M to $9.18M, and earnings per share declined from $0.1765 to $0.1078.
C
Hold
3/9/2020Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 3/9/2020 due to a noticeable decline in the volatility index and total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 3/9/2020 due to a noticeable decline in the volatility index and total return index.
C
Hold
2/21/2020Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 2/21/2020 due to a large increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.3222 to $0.1765, operating cash flow increased 38.83% from $64.24M to $89.18M, and debt to equity declined from 1.08 to 0.99.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 2/21/2020 due to a large increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.3222 to $0.1765, operating cash flow increased 38.83% from $64.24M to $89.18M, and debt to equity declined from 1.08 to 0.99.
C
Hold
1/23/2020Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 1/23/2020 due to a decline in the efficiency index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 1/23/2020 due to a decline in the efficiency index and volatility index.
C
Hold
10/29/2019Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 10/29/2019 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.34 to -$0.3222, net income declined 192.85% from $29.74M to -$27.61M, and EBIT declined 9.13% from $70.35M to $63.93M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 10/29/2019 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.34 to -$0.3222, net income declined 192.85% from $29.74M to -$27.61M, and EBIT declined 9.13% from $70.35M to $63.93M.
C
Hold
5/1/2019Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 5/1/2019 due to an increase in the volatility index, efficiency index and total return index. Net income increased 30.3% from $25.14M to $32.76M, and total capital increased 4.25% from $2.74B to $2.86B.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 5/1/2019 due to an increase in the volatility index, efficiency index and total return index. Net income increased 30.3% from $25.14M to $32.76M, and total capital increased 4.25% from $2.74B to $2.86B.
C
Hold
2/6/2019Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 2/6/2019 due to a decline in the volatility index, valuation index and total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 2/6/2019 due to a decline in the volatility index, valuation index and total return index.
C
Hold
1/14/2019Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 1/14/2019 due to a major decline in the volatility index and total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 1/14/2019 due to a major decline in the volatility index and total return index.
B
Buy
11/26/2018Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to B- from B on 11/26/2018 due to a decline in the volatility index and total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to B- from B on 11/26/2018 due to a decline in the volatility index and total return index.
B
Buy
11/6/2018Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from C+ on 11/6/2018 due to a noticeable increase in the growth index, valuation index and efficiency index. Operating cash flow increased 118.85% from $36.21M to $79.25M, net income increased 16.87% from $11.38M to $13.3M, and earnings per share increased from $0.138 to $0.15.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from C+ on 11/6/2018 due to a noticeable increase in the growth index, valuation index and efficiency index. Operating cash flow increased 118.85% from $36.21M to $79.25M, net income increased 16.87% from $11.38M to $13.3M, and earnings per share increased from $0.138 to $0.15.
C
Hold
10/23/2018Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 10/23/2018 due to a decline in the total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 10/23/2018 due to a decline in the total return index.
B
Buy
10/2/2018Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B- from C+ on 10/2/2018 due to an increase in the total return index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B- from C+ on 10/2/2018 due to an increase in the total return index and volatility index.
C
Hold
9/17/2018Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 9/17/2018 due to a substantial decline in the total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 9/17/2018 due to a substantial decline in the total return index.
B
Buy
8/16/2018Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to B- from B on 8/16/2018 due to a decline in the total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to B- from B on 8/16/2018 due to a decline in the total return index.
B
Buy
7/27/2018Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from C on 7/27/2018 due to a significant increase in the growth index, solvency index and valuation index. Debt to equity declined from 1.84 to 1.1, the quick ratio increased from 1.4 to 1.94, and EBIT increased 6.55% from $57.52M to $61.29M.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from C on 7/27/2018 due to a significant increase in the growth index, solvency index and valuation index. Debt to equity declined from 1.84 to 1.1, the quick ratio increased from 1.4 to 1.94, and EBIT increased 6.55% from $57.52M to $61.29M.
C
Hold
5/7/2018Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 5/7/2018 due to a noticeable decline in the growth index and efficiency index. Net income declined 75.22% from $44.36M to $10.99M, earnings per share declined from $0.5565 to $0.1399, and EBIT declined 4.99% from $60.55M to $57.52M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 5/7/2018 due to a noticeable decline in the growth index and efficiency index. Net income declined 75.22% from $44.36M to $10.99M, earnings per share declined from $0.5565 to $0.1399, and EBIT declined 4.99% from $60.55M to $57.52M.
C
Hold
4/11/2018Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 4/11/2018 due to a significant increase in the total return index, efficiency index and valuation index. Net income increased 1,304.08% from $3.16M to $44.36M, and total capital increased 34.58% from $2.09B to $2.81B.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 4/11/2018 due to a significant increase in the total return index, efficiency index and valuation index. Net income increased 1,304.08% from $3.16M to $44.36M, and total capital increased 34.58% from $2.09B to $2.81B.
C
Hold
10/27/2017Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from B- on 10/27/2017 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.14 to $0.04, net income declined 70.84% from $10.84M to $3.16M, and total revenue declined 1.18% from $282.16M to $278.83M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from B- on 10/27/2017 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.14 to $0.04, net income declined 70.84% from $10.84M to $3.16M, and total revenue declined 1.18% from $282.16M to $278.83M.
B
Buy
10/18/2017Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to B- from B on 10/18/2017 due to a substantial decline in the total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to B- from B on 10/18/2017 due to a substantial decline in the total return index.
B
Buy
7/28/2017Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from C on 7/28/2017 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.08 to $0.14, the quick ratio increased from 1.56 to 1.84, and EBIT increased 15.01% from $35.7M to $41.06M.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from C on 7/28/2017 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.08 to $0.14, the quick ratio increased from 1.56 to 1.84, and EBIT increased 15.01% from $35.7M to $41.06M.
C
Hold
7/20/2017Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 7/20/2017 due to a decline in the valuation index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 7/20/2017 due to a decline in the valuation index.
C
Hold
4/28/2017Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B on 4/28/2017 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.3481 to $0.08, debt to equity increased from 0.79 to 1, and EBIT declined 26.06% from $48.28M to $35.7M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B on 4/28/2017 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.3481 to $0.08, debt to equity increased from 0.79 to 1, and EBIT declined 26.06% from $48.28M to $35.7M.
B
Buy
4/27/2017Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from B- on 4/27/2017 due to a noticeable increase in the total return index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from B- on 4/27/2017 due to a noticeable increase in the total return index and volatility index.
B
Buy
4/7/2017Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to B- from B on 4/7/2017 due to a large decline in the growth index, valuation index and total return index. Operating cash flow declined 86.04% from $46.77M to $6.53M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to B- from B on 4/7/2017 due to a large decline in the growth index, valuation index and total return index. Operating cash flow declined 86.04% from $46.77M to $6.53M.
B
Buy
10/31/2016Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from C on 10/31/2016 due to a significant increase in the growth index, efficiency index and valuation index. Net income increased 57.93% from $12.76M to $20.14M, earnings per share increased from $0.32 to $0.5, and EBIT increased 10.93% from $36.55M to $40.54M.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B from C on 10/31/2016 due to a significant increase in the growth index, efficiency index and valuation index. Net income increased 57.93% from $12.76M to $20.14M, earnings per share increased from $0.32 to $0.5, and EBIT increased 10.93% from $36.55M to $40.54M.
C
Hold
5/13/2016Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 5/13/2016 due to a large increase in the total return index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 5/13/2016 due to a large increase in the total return index and volatility index.
C
Hold
4/28/2016Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 4/28/2016 due to a major decline in the volatility index and growth index. Operating cash flow declined 24.5% from $25.39M to $19.17M, earnings per share declined from $0.3892 to $0.31, and EBIT declined 10.27% from $37.86M to $33.97M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 4/28/2016 due to a major decline in the volatility index and growth index. Operating cash flow declined 24.5% from $25.39M to $19.17M, earnings per share declined from $0.3892 to $0.31, and EBIT declined 10.27% from $37.86M to $33.97M.
C
Hold
3/2/2016Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 3/2/2016 due to a noticeable increase in the growth index, efficiency index and solvency index. EBIT increased 21.64% from $31.42M to $38.22M, total revenue increased 6.53% from $226.37M to $241.16M, and debt to equity declined from 1 to 0.95.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 3/2/2016 due to a noticeable increase in the growth index, efficiency index and solvency index. EBIT increased 21.64% from $31.42M to $38.22M, total revenue increased 6.53% from $226.37M to $241.16M, and debt to equity declined from 1 to 0.95.
C
Hold
2/19/2016Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 2/19/2016 due to a decline in the volatility index and total return index.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C on 2/19/2016 due to a decline in the volatility index and total return index.
C
Hold
2/4/2016Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 2/4/2016 due to a noticeable increase in the total return index and volatility index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 2/4/2016 due to a noticeable increase in the total return index and volatility index.
C
Hold
11/6/2015Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C+ on 11/6/2015 due to a major decline in the efficiency index, growth index and valuation index. Net income declined 737.88% from $5M to -$31.88M, earnings per share declined from $0.15 to -$0.9037, and EBIT declined 9.52% from $34.72M to $31.42M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C- from C+ on 11/6/2015 due to a major decline in the efficiency index, growth index and valuation index. Net income declined 737.88% from $5M to -$31.88M, earnings per share declined from $0.15 to -$0.9037, and EBIT declined 9.52% from $34.72M to $31.42M.
C
Hold
10/2/2015Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 10/2/2015 due to an increase in the volatility index and valuation index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 10/2/2015 due to an increase in the volatility index and valuation index.
C
Hold
9/17/2015Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 9/17/2015 due to a substantial decline in the total return index, volatility index and efficiency index. Net income declined 40.39% from $8.38M to $5M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C from C+ on 9/17/2015 due to a substantial decline in the total return index, volatility index and efficiency index. Net income declined 40.39% from $8.38M to $5M.
C
Hold
5/1/2015Downgrade
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 5/1/2015 due to a substantial decline in the growth index and solvency index. Earnings per share declined from $0.5177 to $0.25, EBIT declined 26.11% from $43.69M to $32.28M, and total revenue declined 7.34% from $252.18M to $233.67M.
Integra LifeSciences Holdings Corporation (IART) was downgraded to C+ from B- on 5/1/2015 due to a substantial decline in the growth index and solvency index. Earnings per share declined from $0.5177 to $0.25, EBIT declined 26.11% from $43.69M to $32.28M, and total revenue declined 7.34% from $252.18M to $233.67M.
B
Buy
2/25/2015Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to B- from C+ on 2/25/2015 due to a large increase in the volatility index, total return index and growth index.
Integra LifeSciences Holdings Corporation (IART) was upgraded to B- from C+ on 2/25/2015 due to a large increase in the volatility index, total return index and growth index.
C
Hold
11/10/2014Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 11/10/2014 due to a substantial increase in the growth index, volatility index and efficiency index. EBIT increased 118.67% from $15.35M to $33.56M, net income increased 103.25% from $4.83M to $9.81M, and earnings per share increased from $0.1489 to $0.3.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C+ from C on 11/10/2014 due to a substantial increase in the growth index, volatility index and efficiency index. EBIT increased 118.67% from $15.35M to $33.56M, net income increased 103.25% from $4.83M to $9.81M, and earnings per share increased from $0.1489 to $0.3.
C
Hold
8/15/2014Upgraded
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 8/15/2014 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from $0.0684 to $0.1489, operating cash flow increased 45.52% from $11.25M to $16.38M, and total revenue increased 7.58% from $215.06M to $231.35M.
Integra LifeSciences Holdings Corporation (IART) was upgraded to C from C- on 8/15/2014 due to a noticeable increase in the growth index and solvency index. Earnings per share increased from $0.0684 to $0.1489, operating cash flow increased 45.52% from $11.25M to $16.38M, and total revenue increased 7.58% from $215.06M to $231.35M.
NASDAQ
03/11/2025 4:00PM Eastern
Quotes delayed
